|
1.
|
|
11 p, 379.4 KB |
Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
/
Wu, Yi-Long (Guangdong Lung Cancer Institute) ;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 -  10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433
|
|
|
2.
|
|
14 p, 563.4 KB |
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors : The necessity of repeated molecular analysis
/
González-Larriba, José Luis (Hospital Universitario Clínico San Carlos (Madrid)) ;
Lázaro-Quintela, Martín (Complexo Hospitalario Universitario de Vigo) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Universitat Autònoma de Barcelona
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC) has been the identification of molecular alterations vulnerable to targeted inhibition, such as mutations in the epidermal growth factor receptor (EGFR) gene. [...]
2017 - 10.21037/tlcr.2017.10.03
Translational Lung Cancer Research, Vol. 6 (january 2017) , p. S21-S34
|
|
|
3.
|
|
10 p, 666.8 KB |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
García Gómez, Ramón (Hospital General Universitario Gregorio Marañón) ;
Diz Taín, Pilar (Hospital Universitario de León) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez Aguillo, Maite (Complejo Hospitalario de Navarra) ;
Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Peralta Muñoz, Sergio (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Gutierrez, Vanesa (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Andrade Santiago, Jesús Manuel (Hospital Virgen de la Salud (Toledo)) ;
Aparisi, Francisco (Hospital Virgen de los Lirios) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Vicente Baz, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Amador, Mariluz (AstraZeneca) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. [...]
2018 - 10.1186/s12885-018-4004-7
BMC Cancer, Vol. 18 Núm. 1 (30 2018) , p. 106
|
|
|
4.
|
|
12 p, 2.4 MB |
The use of HPV16-E5, EGFR, and PEGFR as prognostic biomarkers for oropharyngeal cancer patients
/
Taberna, Miren (Hospital Universitari de Bellvitge) ;
Torres, Montserrat (Hospital Universitari de Bellvitge) ;
Alejo, María (Hospital General de l'Hospitalet) ;
Mena, Marisa (Centro de Investigación Biomédica en Red de Cáncer) ;
Tous, Sara (Centro de Investigación Biomédica en Red de Cáncer) ;
Marquez, Sandra (Hospital Universitari de Bellvitge) ;
Pavón, Miquel A. (Hospital Universitari de Bellvitge) ;
León, Xavier (Institut d'Investigació Biomèdica Sant Pau) ;
Garcia Lorenzo, J (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Guix, Marta (Hospital del Mar (Barcelona, Catalunya)) ;
Hijano, Rafael (Hospital del Mar (Barcelona, Catalunya)) ;
Bonfill Abella, Teresa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Aguilà, Antón (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Lozano, Alicia (Hospital Universitari de Bellvitge) ;
Mesía, Ricard (Hospital Universitari de Bellvitge) ;
Alemany, Laia (Hospital Universitari de Bellvitge) ;
Bravo, Ignacio G. (Laboratory MIVEGEC (CNRS IRD Uni Montp)) ;
Universitat Autònoma de Barcelona
Anti-epidermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on deescalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. [...]
2018 - 10.3389/fonc.2018.00589
Frontiers in Oncology, Vol. 8 Núm. DEC (2018) , p. 589
|
|
|
5.
|
|
16 p, 2.1 MB |
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies : a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
/
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Sanmartín, O. (Fundació Institut Valencià d'Oncologia) ;
Gúrpide, A. (Clínica Universidad de Navarra) ;
España, A. (Clínica Universidad de Navarra) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Suh Oh, H.J. (Complejo Hospitalario Universitario de Pontevedra) ;
Aragón, I. (Complejo Hospitalario Universitario de Huelva) ;
Segura, S. (Hospital del Mar (Barcelona, Catalunya)) ;
Beato, C. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Botella, R. (Instituto de Investigación Sanitaria La Fe) ;
Universitat Autònoma de Barcelona
Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). [...]
2019 - 10.1007/s12094-018-1953-x
Clinical & Translational Oncology, Vol. 21 Núm. 5 (january 2019) , p. 556-571
|
|
|
6.
|
|
11 p, 555.4 KB |
LungBEAM : A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
/
Garrido, Pilar (Centro de Investigación Biomédica en Red de Cáncer) ;
Paz-Ares, Luis (Universidad Complutense de Madrid) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Trigo, José Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Bosch-Barrera, J (Hospital Universitari de Girona Doctor Josep Trueta) ;
Garcίa-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
González-Larriba, José Luis (Hospital Universitario Clínico San Carlos (Madrid)) ;
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Viñolas, Núria (Hospital Clínic i Provincial de Barcelona) ;
Camps, Carlos (Hospital General Universitario de Valencia) ;
Insa, Amelia (Hospital Clínico Universitario) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe (València)) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
López-Brea, Marta (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Palacios, José (Hospital Universitario Ramón y Cajal (Madrid)) ;
Felip, Enriqueta (Hospital Universitari Vall d'Hebron)
Objectives: The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non-small cell lung cancer (NSCLC) patients treated with first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs). [...]
2021 - 10.1002/cam4.4135
Cancer Medicine, Vol. 10 Núm. 17 (september 2021) , p. 5878-5888
|
|
|
7.
|
|
19 p, 8.2 MB |
Lysosomal and network alterations in human mucopolysaccharidosis type VII iPSC-derived neurons
/
Bayó-Puxan, Neus (Institut d'Investigació Biomèdica de Bellvitge) ;
Terrasso, Ana Paula (Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica António Xavier) ;
Creyssels, Sophie (University of Montpellier) ;
Simão, Daniel (Universidade Nova de Lisboa. Instituto de Tecnologia Química e Biológica António Xavier) ;
Begon-Pescia, Christina (University of Montpellier) ;
Lavigne, Marina (University of Montpellier) ;
Salinas, Sara (University of Montpellier) ;
Bernex, Florence (University of Montpellier) ;
Bosch i Merino, Assumpció (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Kalatzis, Vasiliki (University of Montpellier) ;
Levade, Thierry (University Paul Sabatier Toulouse-III. Laboratoire de Biochimie Métabolique) ;
Cuervo, Ana Maria (Albert Einstein College of Medicine) ;
Lory, Philippe (University of Montpellier) ;
Consiglio, Antonella (University of Brescia. Department of Molecular and Translational Medicine) ;
Brito, Catarina (NOVA University Lisbon. The Discoveries Centre for Regenerative and Precision Medicine) ;
Kremer, Eric J. (University of Montpellier)
Mucopolysaccharidosis type VII (MPS VII) is a lysosomal storage disease caused by deficient β-glucuronidase (β-gluc) activity. Significantly reduced β-gluc activity leads to accumulation of glycosaminoglycans (GAGs) in many tissues, including the brain. [...]
2018 - 10.1038/s41598-018-34523-3
Scientific reports, Vol. 8 (November 2018) , art. 16644
|
|
|
8.
|
|
12 p, 6.9 MB |
EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
/
Chalela, Roberto (Hospital del Mar (Barcelona, Catalunya)) ;
Bellosillo Paricio, Beatriz (Hospital del Mar (Barcelona, Catalunya)) ;
Curull Serrano, Víctor (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Longarón, Raquel (Hospital del Mar (Barcelona, Catalunya)) ;
Pascual-Guardia, Sergi (Hospital del Mar (Barcelona, Catalunya)) ;
Badenes-Bonet, Diana (Hospital del Mar (Barcelona, Catalunya)) ;
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
Sánchez-Font, Albert (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ;
Gea Guiral, Joaquim (Hospital del Mar (Barcelona, Catalunya))
Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. [...]
2019 - 10.3390/jcm8040529
Journal of clinical medicine, Vol. 8 (april 2019)
|
|
|
9.
|
|
15 p, 691.2 KB |
Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients
/
Riera, Pau (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Rodríguez-Santiago, Benjamín (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Lasa, Adriana (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Gonzalez-Quereda, L. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Martín, Berta (Institut d'Investigació Biomèdica Sant Pau) ;
Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Virgili, Anna C. (Institut d'Investigació Biomèdica Sant Pau) ;
Minguillón Pedreño, Jordi (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Camps-Fajol, Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Surrallés i Calonge, Jordi (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau)
Background: About 40% of RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients undergoing anti-EGFR-based therapy have poor outcomes. Treatment failure is not only associated with poorer prognosis but higher healthcare costs. [...]
2020 - 10.3390/cancers12082245
Cancers, Vol. 12, Num. 8 (August 2020) , art. 2245
|
|
|
10.
|
|
11 p, 2.1 MB |
Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma
/
Ito, Masaoki (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Codony-Servat, Jordi (Institut Universitari Dexeus) ;
Giménez-Capitán, Ana (Institut Universitari Dexeus) ;
Serra-Mitjans, Mireia (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Pérez-Ochoa, Francisco (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Llige, David (Institut Germans Trias i Pujol) ;
Chaib, Imane (Institut Germans Trias i Pujol) ;
Rami-Porta, Ramon (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Obiols, Carme (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Call, Sergi (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Iglesias, Manuela (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Belda, José (Belda Sanchis) (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Tarroch-Sarasa, Xavier (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Karachaliou, Niki (Institut Universitari Dexeus) ;
Molina-Vila, Miguel Ángel (Institut Universitari Dexeus) ;
Okada, Morihito (Hiroshima University. Department of Surgical Oncology) ;
Rosell, Rafael (Institut Germans Trias i Pujol)
EGFR mutation-positive lung adenocarcinoma (LUAD) displays impaired phosphorylation of ERK and Src-homology 2 domain-containing phosphatase 2 (SHP2) in comparison with EGFR wild-type LUADs. We hypothesize that SHP2 expression could be predictive in patients positive with resected EGFR mutation versus patients with EGFR wild-type LUAD. [...]
2020 - 10.1016/j.jtocrr.2020.100084
JTO Clinical and Research Reports, Vol. 1 Núm. 4 (august 2020)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
